KR20240063899A - 세포의 처리 방법 - Google Patents

세포의 처리 방법 Download PDF

Info

Publication number
KR20240063899A
KR20240063899A KR1020247008687A KR20247008687A KR20240063899A KR 20240063899 A KR20240063899 A KR 20240063899A KR 1020247008687 A KR1020247008687 A KR 1020247008687A KR 20247008687 A KR20247008687 A KR 20247008687A KR 20240063899 A KR20240063899 A KR 20240063899A
Authority
KR
South Korea
Prior art keywords
cells
solution
concentration
activity
thawing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247008687A
Other languages
English (en)
Korean (ko)
Inventor
유이 하라다
요시카즈 요네미츠
Original Assignee
가부시키가이샤 가이아바이오메디신
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 가이아바이오메디신 filed Critical 가부시키가이샤 가이아바이오메디신
Publication of KR20240063899A publication Critical patent/KR20240063899A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247008687A 2021-09-08 2022-09-07 세포의 처리 방법 Pending KR20240063899A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2021-146461 2021-09-08
JP2021146461 2021-09-08
PCT/JP2022/033487 WO2023038037A1 (ja) 2021-09-08 2022-09-07 細胞の処理方法

Publications (1)

Publication Number Publication Date
KR20240063899A true KR20240063899A (ko) 2024-05-10

Family

ID=85507641

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247008687A Pending KR20240063899A (ko) 2021-09-08 2022-09-07 세포의 처리 방법

Country Status (8)

Country Link
US (1) US20240366673A1 (https=)
EP (1) EP4400576A4 (https=)
JP (1) JPWO2023038037A1 (https=)
KR (1) KR20240063899A (https=)
CN (1) CN118103492A (https=)
AU (1) AU2022342919A1 (https=)
TW (1) TW202315937A (https=)
WO (1) WO2023038037A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024234571A1 (en) * 2023-03-15 2025-09-25 Gaia Biomedicine Inc. Solution for suspending cells and use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4947948B1 (https=) 1970-05-21 1974-12-18
WO2002001952A1 (fr) 2000-07-05 2002-01-10 Hiromi Wada Fluide de preservation pour cellules et tissus
JP2002233356A (ja) 2000-12-04 2002-08-20 Human Tekku:Kk 細胞の保存液および該保存液を用いた細胞の保存方法
JP2006230396A (ja) 2004-10-12 2006-09-07 Nipro Corp 細胞保存液
WO2011021618A1 (ja) 2009-08-19 2011-02-24 タカラバイオ株式会社 細胞の保存方法
WO2013115322A1 (ja) 2012-02-02 2013-08-08 タカラバイオ株式会社 細胞の保存方法
JP2013233102A (ja) 2012-05-08 2013-11-21 Otsuka Pharmaceut Factory Inc トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2652666T3 (es) * 2011-12-22 2018-02-05 Mogam Biotechnology Institute Procedimiento de producción de linfocitos citolíticos naturales, linfocitos citolíticos naturales producidos de este modo y composición para el tratamiento de cánceres y enfermedades infecciosas que contienen los mismos
CN114134113A (zh) * 2012-08-13 2022-03-04 人类起源公司 自然杀伤细胞及其用途
US20180021378A1 (en) * 2014-12-31 2018-01-25 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
MY201637A (en) * 2015-10-15 2024-03-06 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
FR3074018B1 (fr) * 2017-11-27 2020-09-11 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
EP3720950B1 (en) * 2017-12-05 2025-09-03 Celyad S.A. Reducing fratricide of immune cells expressing nkg2d-based receptors
JP6543375B1 (ja) 2018-03-27 2019-07-10 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
US20210267190A1 (en) * 2018-07-10 2021-09-02 Nantkwest, Inc. Cryopreservation
CN113454207A (zh) * 2018-11-30 2021-09-28 细胞结构公司 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
US11660423B2 (en) * 2019-08-28 2023-05-30 Becton, Dickinson And Company Catheter system with extendable extension tube
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
JP7793284B2 (ja) 2020-03-02 2026-01-05 株式会社ガイアバイオメディシン 高活性ｎｋ細胞の処理方法
EP4173640A4 (en) * 2020-06-30 2024-08-14 GAIA BioMedicine Inc. METHOD FOR STABILIZING THE BINDING OF AN ANTIBODY ON AN NK CELL AND ASSOCIATED USE

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4947948B1 (https=) 1970-05-21 1974-12-18
WO2002001952A1 (fr) 2000-07-05 2002-01-10 Hiromi Wada Fluide de preservation pour cellules et tissus
JP2002233356A (ja) 2000-12-04 2002-08-20 Human Tekku:Kk 細胞の保存液および該保存液を用いた細胞の保存方法
JP2006230396A (ja) 2004-10-12 2006-09-07 Nipro Corp 細胞保存液
WO2011021618A1 (ja) 2009-08-19 2011-02-24 タカラバイオ株式会社 細胞の保存方法
WO2013115322A1 (ja) 2012-02-02 2013-08-08 タカラバイオ株式会社 細胞の保存方法
JP2013233102A (ja) 2012-05-08 2013-11-21 Otsuka Pharmaceut Factory Inc トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Liu E, et al. N Engl J Med. 2020 ; 382 : 545-53
WO2021/177279 (PCT/JP2021/007863, 본원의 우선일에는 미공개)

Also Published As

Publication number Publication date
AU2022342919A1 (en) 2024-03-14
CN118103492A (zh) 2024-05-28
US20240366673A1 (en) 2024-11-07
EP4400576A4 (en) 2025-10-15
TW202315937A (zh) 2023-04-16
WO2023038037A1 (ja) 2023-03-16
EP4400576A1 (en) 2024-07-17
JPWO2023038037A1 (https=) 2023-03-16

Similar Documents

Publication Publication Date Title
AU2014300400B2 (en) Trehalose and dextran-containing solution for transplanting mammalian cells
Yuan et al. Cryopreservation of human mesenchymal stromal cells expressing TRAIL for human anti-cancer therapy
US20230109717A1 (en) Method for treating highly active nk cells
JP6561173B2 (ja) 哺乳動物細胞投与用液
KR102784950B1 (ko) 포유동물 세포의 보존액
JP2022088551A (ja) 増殖造血幹細胞／前駆細胞集団の利用
US11785937B2 (en) Method for the cryopreservation of cells for therapeutic purposes
KR20240063899A (ko) 세포의 처리 방법
WO2013115322A1 (ja) 細胞の保存方法
WO2021213446A1 (zh) 生物样品低温储存
EP4682242A1 (en) Solution for suspending cells, and use of same
HK40108875A (en) Method for treating cells
KR100569609B1 (ko) 세포면역치료제의 제조를 위한 림프구 장기 보관 방법
HK40106614A (zh) 细胞的处理方法
HK40084673A (en) Method for treating highly active nk cells
HK40083554A (en) Method for treating highly active nk cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240314

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250318

Comment text: Request for Examination of Application